Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Sponsor
Henan Cancer Hospital
Study ID
NCT04948125
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Gastric Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.

Key Dates

Start date
Apr 28, 2021
Status verified
Jun 2021
Primary completion
Jun 3, 2022
Completion
Aug 3, 2023

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    camrelizumab combined with apatinib

Primary Outcome Measure

Objective response rate(ORR) [ Time Frame: up to 1 years ]

Central Contacts

Related Studies